Two cycles of bleomycin, etoposide, and cisplatin (BEP) were evaluated as adjuvant chemotherapy for patients with pathological stage II non-seminomatous germ cell tumours. Between 1985 and 1995, 86 patients with pathological stage II non-seminomatous testicular cancer were treated with two cycles of BEP. At retroperitoneal lymph node dissection (RPLND) 49 patients (57%) had pathological stage II(A) (microscopic nodal metastases) and 37 (43%) had stage II(B) (gross nodal metastases). After RPLND, the patients received bleomycin, 30 units weekly for 8 weeks, etoposide (100 mg/m(2)) and cisplatin (20 mg/m(2)) each for 5 days every 28 days for two cycles as adjuvant chemotherapy. 4 patients were lost to follow-up. 10 patients (12%) developed granulocytopenic fever during their chemotherapy. Of the 82 evaluable patients all remained with no evidence of disease except for a single patient with a cervical nodal relapse of teratoma. This was resected and he remains disease free. Median follow
|Pages (from-to)||472 - 475|
|Journal||European Journal of Cancer|
|Publication status||Published - 2000|
- Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Germinoma/*drug therapy, Testicular Neoplasms/*drug therapy, Bleomycin/administration & dosage, Chemotherapy, Adjuvant, Cisplatin/administration & dosage, Drug Administration Schedule, Etoposide/administration & dosage, Follow-Up Studies, Germinoma/pathology, Germinoma/surgery, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Retrospective Studies, Testicular Neoplasms/pathology, Testicular Neoplasms/surgery
Behnia, M., Foster, R., Einhorn, L. H., Donohue, J., & Nichols, C. R. (2000). Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. European Journal of Cancer, 36(4), 472 - 475.